MoonLake Immunotherapeutics (MLTX) Net Cash Flow Growth (1y) (2022 - 2026)
MoonLake Immunotherapeutics (MLTX) Net Cash Flow Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | - |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 53.46% |
| 10 | MoonLake Immunotherapeutics | 1.41 Bn | 1.05 Bn | - | -138.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -138.96% |
| Dec 31, 2025 | 91.66% |
| Sep 30, 2025 | 33.60% |
| Jun 30, 2025 | 129.16% |
| Mar 31, 2025 | 1,162.50% |
| Dec 31, 2024 | -247.18% |
| Sep 30, 2024 | 118.07% |
| Jun 30, 2024 | -125.59% |
| Mar 31, 2024 | -31.98% |
| Dec 31, 2023 | 7,962.69% |
| Sep 30, 2023 | -256.02% |
| Jun 30, 2023 | 438.34% |
| Mar 31, 2023 | 1,225.00% |
| Dec 31, 2022 | -121.04% |
| Sep 30, 2022 | -3,266.85% |
| Jun 30, 2022 | 3,668.46% |
| Mar 31, 2022 | 583.44% |